Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:VT-464
oral selective CYP17 lyase inhibitors |
| gptkbp:focusesOn |
oncology
endocrine diseases |
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina
|
| https://www.w3.org/2000/01/rdf-schema#label |
Innocrin Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:website |
https://www.innocrinpharma.com/
|
| gptkbp:bfsParent |
gptkb:Fred_Eshelman
|
| gptkbp:bfsLayer |
6
|